Pfizer’s eczema drug clears skin in mid-stage trial
Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.